Sotatercept for Pulmonary Arterial Hypertension
(HYPERION Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing sotatercept, a new medication, to see if it can help people with a specific type of high blood pressure in the lungs (PAH) when added to their usual treatment. The study focuses on patients who are newly diagnosed and at higher risk of their condition worsening. Sotatercept aims to reduce the pressure in the lung's blood vessels, potentially slowing down disease progression. Sotatercept has shown significant reduction in pulmonary vascular resistance and maintained clinical efficacy in previous studies.
Do I need to stop my current medications to join the trial?
The trial does not specify that you need to stop your current medications. In fact, participants must be on stable doses of a double or triple combination of background PAH therapies and diuretics for at least 90 days prior to screening. However, you should discuss your specific medications with the trial team to ensure they are compatible with the study requirements.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must be on stable doses of your current PAH therapies and diuretics for at least 90 days before joining the study.
What safety data is available for sotatercept in treating pulmonary arterial hypertension?
The safety data for sotatercept in treating pulmonary arterial hypertension has been evaluated in several studies. The PULSAR open-label extension study reported cumulative safety data for sotatercept over 18-24 months, indicating a significant reduction in pulmonary vascular resistance compared to placebo. The STELLAR trial also assessed sotatercept's safety and efficacy, showing improvements in 6-minute walk distance when added to stable background therapy. These studies suggest that sotatercept has been investigated for both short-term and longer-term safety in clinical trials.12345
Is sotatercept safe for humans?
Is the drug Sotatercept a promising treatment for Pulmonary Arterial Hypertension?
Yes, Sotatercept is a promising drug for Pulmonary Arterial Hypertension. It has been shown to improve walking distance and reduce resistance in blood vessels, which are important for patients with this condition. It also aims to balance growth signals in the body, potentially improving long-term health outcomes.12346
What makes the drug sotatercept unique for treating pulmonary arterial hypertension?
Sotatercept is unique because it is a fusion protein that targets and traps activins and growth differentiation factors, which are involved in the disease process of pulmonary arterial hypertension. This mechanism aims to restore balance between growth-promoting and growth-inhibiting signals, offering a novel approach compared to existing treatments.12346
What data supports the idea that Sotatercept for Pulmonary Arterial Hypertension is an effective drug?
The available research shows that Sotatercept is effective for treating Pulmonary Arterial Hypertension. In one study, adding Sotatercept to existing treatments helped patients walk farther in six minutes after 24 weeks. Another study found that Sotatercept significantly reduced the resistance in blood vessels in the lungs compared to a placebo. These improvements suggest that Sotatercept can help manage the condition better than some other treatments.12367
What data supports the effectiveness of the drug sotatercept for pulmonary arterial hypertension?
Research shows that adding sotatercept to existing treatments for pulmonary arterial hypertension (a type of high blood pressure affecting the lungs) improved patients' ability to walk further in 6 minutes after 24 weeks. Additionally, sotatercept significantly reduced the resistance in blood vessels in the lungs compared to a placebo, showing its potential to help manage this condition.12367
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for adults over 18 with newly diagnosed Pulmonary Arterial Hypertension (PAH) who are at intermediate or high risk of disease progression. They must be able to walk a certain distance and adhere to the study's schedule. Women of childbearing age and men must follow strict contraception guidelines.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive sotatercept or placebo plus background PAH therapy administered subcutaneously every 21 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term in the MK-7962-004 extension study or by commercial access
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Sotatercept
Find a Clinic Near You
Who Is Running the Clinical Trial?
Acceleron Pharma Inc.
Lead Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Lead Sponsor
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Lead Sponsor